Avastin nabs second-in-a-row priority review, this time in ovarian cancer

Tracy Staton

Last week, it was for cervical . week, it's the fast track for difficult-to-treat .

FiercePharma News

Share This Post

Related Articles

Leave a Reply

© 2018 Global Regulatory Science. All rights reserved. Site Admin · Entries RSS · Comments RSS